Dulaglutide
Dulaglutide (Trulicity) is a once-weekly GLP-1 receptor agonist for type 2 diabetes. Its larger molecular size from fusion with an Fc fragment extends half-life and may reduce some GI side effects.
Mechanism of Action
GLP-1 analog fused to a modified human IgG4 Fc fragment, providing extended duration of action. Activates GLP-1 receptors for glucose-dependent insulin secretion and appetite suppression.
Dosage Overview
Dose Range
750 mcg – 4.5 mg
Route
subcutaneous
Frequency
Weekly
Cycle Length
12–52 weeks
Reconstitution
Typical Dosage (Research)
Start at 0.75mg once weekly, may increase to 1.5mg, 3mg, or maximum 4.5mg weekly based on glycemic response.
Subcutaneous injection once weekly, any time of day, with or without food. Comes in pre-filled single-dose pens.
Considerations for Men & Women
Women: Same pregnancy contraindications as other GLP-1 agonists — discontinue before planned conception. May affect oral contraceptive absorption. Weekly dosing. Can improve PCOS-related symptoms through weight loss and insulin sensitization.
Men: May improve testosterone levels secondary to weight loss in obese men. Weekly injection schedule is identical for both sexes. No sex-specific dose adjustments.
Individual responses vary. These notes reflect general trends from research literature and are not medical advice.
Quick Calculator
Quick Calculator
Concentration: 3,000 mcg/ml
Volume to inject: 0.25 ml
Syringe units (U-100): 25.0 units
Pre-filled with Dulaglutide defaults. Adjust values as needed.
Side Effects & Risks
Nausea, diarrhea, vomiting, abdominal pain, decreased appetite. Generally well-tolerated with gradual dose titration.
Same class warnings: thyroid tumors, pancreatitis, diabetic retinopathy complications. Avoid in severe GI disease.
Who Uses Dulaglutide
Type 2 diabetics preferring once-weekly dosing, those seeking cardiovascular benefits (shown to reduce MACE), patients wanting moderate weight loss.
Similar Peptides
View All Alternatives →Setmelanotide (Imcivree) is an FDA-approved MC4R agonist for chronic weight management in patients with obesity due to specific genetic conditions (POMC, PCSK1, or LEPR deficiency).
Mod GRF 1-29 (Modified GRF 1-29, also called CJC-1295 without DAC or Tetrasubstituted GRF 1-29) is a modified growth hormone-releasing hormone analog with improved stability over natural GHRH.
Cagrilintide is a long-acting amylin analog in development, showing promising results when combined with semaglutide (CagriSema). Amylin is a hormone co-secreted with insulin that promotes satiety.
Semaglutide is a GLP-1 receptor agonist that has revolutionized weight management and diabetes treatment. FDA-approved as Ozempic (diabetes), Wegovy (weight loss), and Rybelsus (oral form), it has become one of the most prescribed peptides worldwide.
HGH Fragment 176-191 is the fat-reducing portion of the growth hormone molecule. Unlike AOD-9604 (which has an additional tyrosine), this is the exact fragment of HGH responsible for lipolytic effects.